Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 97. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Health insurance system in Japan faces risk of politicisation776
Navigating the complexity: reflections on the development of perioperative cancer treatments644
Dual therapy in metastatic castration-resistant prostate cancer572
US FDA proposes stronger laboratory test oversight522
Enhancing equity and long-term impact assessments in radiotherapy environmental studies470
Palliative radiotherapy for hepatic cancer pain450
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply449
SANO trial: innovations, risks, and unanswered questions392
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia388
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study387
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o386
Toxicity assessment bias in the PACE-C trial – Authors' reply368
New national cancer registry for France339
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX336
The future of precise cancer chronotherapeutics306
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply295
Antibody–drug conjugates in acute myeloid leukaemia: more research needed281
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply277
Study bolsters concerns about US FDA accelerated drug approvals277
Olanzapine for chemotherapy-induced nausea and vomiting control277
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy262
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer253
Combination immunotherapy in chemotherapy in gastric cancer249
Use of artificial intelligence to enhance detection of nodal metastases248
The GLOW trial in chronic lymphocytic leukaemia244
Patients with cancer in Louisiana denied fertility preservation cover244
Precision medicine for children with cancer243
Concern for cancer drugs in USA–EU tariff war242
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation237
IVLBCL mimicking VEXAS syndrome223
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies216
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer213
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment213
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial213
Italy to pass law on the right to be forgotten for cancer survivors211
US Surgeon General calls for cancer warning labels on alcohol210
Correction to Lancet Oncol 2022; 23: 1124–26201
Correction to Lancet Oncol 2021; 22: 1081–92199
Innovation in gynaecological cancer: highlighting global disparities192
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges191
The silent malignant mesothelioma epidemic: a call to action185
Determining the optimal use of approved drugs in oncology185
A new generation of comprehensive precision oncology trials184
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospec183
Clinical benefit and the Trump administration's cancer medicine reforms175
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis174
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries173
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult173
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial166
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t165
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus163
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas163
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study162
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial160
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 158
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, 152
Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers144
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial140
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi139
Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer138
ALND after neoadjuvant chemotherapy: a call for caution138
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm138
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer136
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 136
Mantle cell lymphoma: is it time for risk-adapted treatment?133
Cancer on the agenda during IAEA Director General's visit to Chile132
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire132
Lung cancer rates highest among British Bangladeshi men132
Balancing clinical benefit and social value: challenges in HTA assessments131
Daratumumab maintenance in patients with myeloma130
Challenges and prospects for cancer treatment in prison settings126
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group122
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra121
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:119
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis118
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus117
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update116
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study114
A biobank perspective on use of tissue samples donated by trial participants113
Common Sense Oncology: including everyone113
Clearing the radiotherapy backlog: innovation to pave the way113
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer111
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer108
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?108
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study107
Importance of clinical research for the UK's 10-year cancer plan107
Essential anticancer medicines for children: defining what matters most for Europe107
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer105
Oral contraceptives and risk of liver cancer104
WHO reports health service disruptions due to suspensions of aid104
Systemic therapy for brain metastases: a changing landscape102
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply101
ESMO Congress 2025101
Correction to Lancet Oncol 2020; 21: 699–70999
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit99
Correction to Lancet Oncol 2023; 24: e24297
2022 ASTRO annual meeting97
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA97
0.1394739151001